trial · primary record
Macitentan 10 mg
Pulmonary Arterial Hypertension
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 935 |
| Primary completion | 2029-02-20 |
| Primary endpoint | Double-blind Treatment Period: Time to First Clinical Events Committee (CEC)-adjudicated Morbidity or Mortality (M/M) Events |
| Registry ID | NCT04273945 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:08.639Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04273945
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.